<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04605107</url>
  </required_header>
  <id_info>
    <org_study_id>GRC/1/13/433</org_study_id>
    <nct_id>NCT04605107</nct_id>
  </id_info>
  <brief_title>Biosimilarity Study of IM Injection of Human Chorionic Gonadotrophin After Parenteral Administration of Treatment A TEST Product Epifasi 5000 I.U. Ampoules (EIPICO PHARMA, EGYPT) and Treatment B REFERENCE Product Pregnyl 5000 I.U. Ampoules (Baxter Pharmaceutical Solutions for Organon, USA).</brief_title>
  <official_title>Comparative Randomized, Single Dose, Parallel, Triple-blinded Study in Infertile Females to Evaluate Biosimilarity of IM Injection of Human Chorionic Gonadotrophin After Parenteral Administration of Treatment A TEST Product Epifasi 5000 I.U. Ampoules (EIPICO PHARMA, EGYPT) and Treatment B REFERENCE Product Pregnyl 5000 I.U. Ampoules (Baxter Pharmaceutical Solutions for Organon, USA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genuine Research Center, Egypt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EIPICO PHARMA, EGYPT</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genuine Research Center, Egypt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparative randomized, single dose, parallel, triple-blinded study in infertile females to&#xD;
      evaluate biosimilarity of IM Injection of Human Chorionic Gonadotrophin (HCG) after&#xD;
      Parenteral administration of Treatment A TEST Product Epifasi 5000 I.U. Ampoules (EIPICO&#xD;
      PHARMA, EGYPT) and Treatment B REFERENCE Product Pregnyl 5000 I.U. Ampoules (Baxter&#xD;
      Pharmaceutical Solutions for Organon, USA)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the biosimilarity of Human chorionic gonadotropin (HCG) from Epifasi IM&#xD;
      Injection (EIPICO Pharma Egypt) and Pregnyl IM Injection (Baxter Pharmaceutical Solutions for&#xD;
      Organon, USA) after a single IM dose administration of each to healthy adult will be&#xD;
      investigated to determining the study variables: Ovarian Ultrasonic counting mature grafian&#xD;
      follicles, Number of retrieved oocytes and their grades.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 30, 2013</start_date>
  <completion_date type="Actual">March 8, 2015</completion_date>
  <primary_completion_date type="Actual">January 8, 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>No. of mature follicles</measure>
    <time_frame>Up to 34-36 hours post dose</time_frame>
    <description>A dose of Epifasi 5000 I.U. Ampoule was injected to trigger ovulation., At least, one mature follicle should be detected with a diameter of 18 mm or more &amp; two additional follicles reached a diameter of 16 mm or more. 34 to 36 hours later oocytes were retrieved.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Evaluation</measure>
    <time_frame>the patient is observed during the whole course of the study and for one month post study</time_frame>
    <description>Any reported adverse effect from the patient side or observed by the investigator, Also any abnormal lab finding.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>A test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epifasi 5000 I.U. Ampoules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pregnyl 5000 I.U. Ampoules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epifasi: Human chorionic gonadotrophin</intervention_name>
    <description>IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin</description>
    <arm_group_label>A test</arm_group_label>
    <other_name>Epifasi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregnyl: Human chorionic gonadotrophin</intervention_name>
    <description>IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin</description>
    <arm_group_label>B reference</arm_group_label>
    <other_name>Pregnyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Premenopausal woman between 18 - 40 years of age.&#xD;
&#xD;
          2. Body mass index (BMI) of 32 or less.&#xD;
&#xD;
          3. A menstrual cycle lasting between 21 and 35 days.&#xD;
&#xD;
          4. Serum hormone levels of FSH 12 IU/L or less, PRL 1040 mIU/L or less, and TSH within&#xD;
             the normal range of 0.3- 4.9 mIU/L&#xD;
&#xD;
          5. Patient having both ovaries and a normal uterine cavity confirmed by hysteroscopy, or&#xD;
             hysterosalpingography.&#xD;
&#xD;
          6. All patients had to be infertile due to at least one of the following causes and must&#xD;
             have justified ART (Assisted Reproductive Technology) treatment: tubal factor, mild&#xD;
             endometriosis (American Fertility Society classification stage I orII), unexplained&#xD;
             infertility, or male factor&#xD;
&#xD;
          7. Patients achieving good ovarian response and considered to receive hCG for final&#xD;
             follicular maturation prior to OPU.&#xD;
&#xD;
          8. Written and signed informed consent by the patient.&#xD;
&#xD;
          9. Subject does not have allergy to the drugs under investigation.&#xD;
&#xD;
         10. Medical demographics without evidence of clinically significant deviation from rather&#xD;
             normal medical condition.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with low ovarian reserve, as proved by hormonal assays and basal antral&#xD;
             follicular count.&#xD;
&#xD;
          2. More than three previous assisted reproductive technology cycle or treatment with&#xD;
             clomiphene citrate or gonadotropins for at least 1 month before screening,&#xD;
&#xD;
          3. Patients with pelvic abnormality that would interfere with ovarian accessibility for&#xD;
             OPU, e.g. ovarian endometriotic cysts or high and retro-uterine ovary.&#xD;
&#xD;
          4. Patients not achieving a satisfactory ovarian response on ovulation induction, whether&#xD;
             poor response (3 or less mature ovarian follicles) or over-response with high&#xD;
             likelihood of developing ovarian hyperstimulation syndrome (OHSS) on triggering with&#xD;
             HCG.&#xD;
&#xD;
          5. History of hypersensitivity to the study medications or to drugs with similar chemical&#xD;
             structure.&#xD;
&#xD;
          6. Patients unlikely to comply with the protocol, e.g. uncooperative attitude, inability&#xD;
             to return for follow-up visits, and likelihood of not completing the study.&#xD;
&#xD;
          7. Mental condition rendering the patients unable to understand the nature, scope and&#xD;
             possible consequences of the study.&#xD;
&#xD;
          8. Results of laboratory tests which are clinically significant.&#xD;
&#xD;
          9. Acute infection within one week preceding first study drug administration.&#xD;
&#xD;
         10. History of drug or alcohol abuse.&#xD;
&#xD;
         11. Subject does not agree not to take any prescription or non-prescription drugs within&#xD;
             two weeks before first study drug administration and until the end of the study.&#xD;
&#xD;
         12. Subject is on a special diet (for example subject is vegetarian).&#xD;
&#xD;
         13. Subject does not agree not to consume any beverages or foods containing&#xD;
             methyl-xanthenes e.g. caffeine (coffee, tea, cola, chocolate etc.) 48 hours prior to&#xD;
             the study administration of either study period until donating the last sample in each&#xD;
             respective period.&#xD;
&#xD;
         14. Subject does not agree not to consume any beverages or foods containing grapefruit 7&#xD;
             days prior to first study drug administration until the end of the study.&#xD;
&#xD;
         15. Subject has a history of severe diseases which have direct impact on the study.&#xD;
&#xD;
         16. Participation in a biosimilarity study or in a clinical study within the last 6 weeks&#xD;
             before first study drug administration.&#xD;
&#xD;
         17. Subject intends to be hospitalized within 3 months after first study drug&#xD;
             administration.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Infertile and anovulatory females of age 18-40 years, BMI â‰¤32, Menstrual cycle lasting between 21-35 days, Hormones (FSH, PRL and TSH) within normal levels, two ovaries and a normal uterine cavity and Justified for ART as a result of tubal factor, mild endometriosis, unexplained or male factor.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Elshafeey, Ph.D. Pharma</last_name>
    <role>Study Director</role>
    <affiliation>Genuine Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Genuine Research Center GRC</name>
      <address>
        <city>Cairo</city>
        <zip>11757</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://www.pharmaweb.net/pwmirror/pw9/ifpma/ich1.html</url>
    <description>International conference of harmonization of technical requirements for registration of pharmaceuticals for human use. ICH harmonized tripartite guideline. Guidelines for good clinical practice. May 1996.</description>
  </link>
  <link>
    <url>https://www.ema.europa.eu</url>
    <description>The European Agency for the Evaluation of Medicinal products (EMEA). Note for guidance on good clinical practice (CPMP/ICH/135/95), May 1997.</description>
  </link>
  <link>
    <url>https://www.fda.gov/drugs/guidance-compliance-regulatory-information</url>
    <description>Guidance for Industry: Bioavailability and Bioequivalence studies for orally administered drug products-general considerations. US Dept. of Health and Human Services, food and drug administration (FDA), center for drug evaluation and research (CDER), M</description>
  </link>
  <reference>
    <citation>Steinijans VW, Diletti E. Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals. Eur J Clin Pharmacol. 1983;24(1):127-36.</citation>
    <PMID>6832195</PMID>
  </reference>
  <reference>
    <citation>Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987 Dec;15(6):657-80.</citation>
    <PMID>3450848</PMID>
  </reference>
  <reference>
    <citation>Driscoll GL, Tyler JP, Hangan JT, Fisher PR, Birdsall MA, Knight DC. A prospective, randomized, controlled, double-blind, double-dummy comparison of recombinant and urinary HCG for inducing oocyte maturation and follicular luteinization in ovarian stimulation. Hum Reprod. 2000 Jun;15(6):1305-10.</citation>
    <PMID>10831560</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

